Source comparison
Mechanism Differences: Ghrelin Mimetic vs GHRH Analog
MK-677 functions as a selective ghrelin receptor agonist. It binds to GHSR1a (growth hormone secretagogue receptor 1a) with nanomolar affinity, triggering the same intracellular cascade that endogenous ghrelin activates. This elevates both growth hormone and p
This comparison does not assign a generated winner or score.
- MK-677 functions as a selective ghrelin receptor agonist. It binds to GHSR1a (growth hormone secretagogue receptor 1a) with nanomolar affinity, triggering the same intracellular cascade that endogenous ghrelin activates. This elevates both growth hormone and prolactin while simultaneously stimulating orexigenic (appetite-promoting) pathways in the arcuate nucleus. The result: sustained GH elevation without pulsatile peaks, elevated baseline IGF-1 (typically 50–90% above baseline within two weeks), and marked increases in hunger signaling that persist throughout treatment. Insulin sensitivity declines in proportion to dose and duration. Fasting glucose can rise 10–15 mg/dL after six months at 25 mg daily.
- Tesamorelin is a synthetic analog of human GHRH (growth hormone-releasing hormone) with a trans-3-hexenoic acid substitution at the N-terminus, extending the peptide's half-life to approximately 26 minutes (versus 7 minutes for native GHRH). It binds GHRH receptors on anterior pituitary somatotrophs, restoring physiological GH pulsatility rather than creating sustained elevation. IGF-1 increases are dose-dependent (mean 181 ng/mL increase at 2 mg daily in the TRIM trial) without the appetite surge or insulin resistance seen with ghrelin mimetics. The mechanism preserves negative feedback loops. GH secretion remains responsive to somatostatin inhibition, unlike exogenous HGH administration which bypasses pituitary regulation entirely.
- MK 677 from Real Peptides is synthesized with exact amino-acid sequencing to match the published structure of ibutamoren mesylate, ensuring consistency across batches for research applications requiring reliable ghrelin receptor agonism.